MA35281B1 - Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques - Google Patents
Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiquesInfo
- Publication number
- MA35281B1 MA35281B1 MA36703A MA36703A MA35281B1 MA 35281 B1 MA35281 B1 MA 35281B1 MA 36703 A MA36703 A MA 36703A MA 36703 A MA36703 A MA 36703A MA 35281 B1 MA35281 B1 MA 35281B1
- Authority
- MA
- Morocco
- Prior art keywords
- paclitaxel
- assay
- treatment
- administration
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des méthodes et des compositions pour le traitement clinique de cancers gynécologiques avancés à l'aide d'anticorps anti-erbb3 combinés avec le paclitaxel.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161503342P | 2011-06-30 | 2011-06-30 | |
US201161529630P | 2011-08-31 | 2011-08-31 | |
FR1250860 | 2012-01-30 | ||
US201261596102P | 2012-02-07 | 2012-02-07 | |
PCT/US2012/042164 WO2013003037A2 (fr) | 2011-06-30 | 2012-06-13 | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35281B1 true MA35281B1 (fr) | 2014-07-03 |
Family
ID=47424747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36703A MA35281B1 (fr) | 2011-06-30 | 2014-01-22 | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques |
Country Status (15)
Country | Link |
---|---|
US (1) | US20140248280A1 (fr) |
EP (1) | EP2726100A4 (fr) |
JP (1) | JP2014527035A (fr) |
KR (1) | KR20140063578A (fr) |
CN (1) | CN103945866A (fr) |
AU (1) | AU2012275850A1 (fr) |
BR (1) | BR112013033544A2 (fr) |
CA (1) | CA2839869A1 (fr) |
CO (1) | CO6862110A2 (fr) |
EA (1) | EA201490180A1 (fr) |
MA (1) | MA35281B1 (fr) |
MX (1) | MX2013015333A (fr) |
TW (1) | TW201317002A (fr) |
UY (1) | UY34178A (fr) |
WO (1) | WO2013003037A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
WO2014072305A1 (fr) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Protéines de liaison à l'antigène anti-her3/her4 se liant à la boucle en épingle à cheveux beta |
WO2015100459A2 (fr) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
WO2016011167A1 (fr) * | 2014-07-16 | 2016-01-21 | Dana-Farber Cancer Institute, Inc., Et Al | Inhibition de her3 dans les cancers ovariens séreux à évolution lente |
CN107750165A (zh) | 2015-04-17 | 2018-03-02 | 梅里麦克制药股份有限公司 | 借助塞里班土单抗的组合治疗 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
EP3429623A1 (fr) | 2016-03-15 | 2019-01-23 | Merrimack Pharmaceuticals, Inc. | Méthodes de traitement du cancer du sein er+, her2-hrg+ à l'aide de traitements d'association comportant un anticorps anti-erbb3 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008073629A2 (fr) * | 2006-11-03 | 2008-06-19 | Board Of Regents, The University Of Texas System | Predicteurs bifonctionnels de sensibilite et de resistance a un traitement anti-cancereux |
SI2129396T1 (sl) * | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
PL2544680T3 (pl) * | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
-
2012
- 2012-06-13 CN CN201280041592.0A patent/CN103945866A/zh active Pending
- 2012-06-13 CA CA2839869A patent/CA2839869A1/fr not_active Abandoned
- 2012-06-13 WO PCT/US2012/042164 patent/WO2013003037A2/fr active Application Filing
- 2012-06-13 KR KR1020147002211A patent/KR20140063578A/ko not_active Application Discontinuation
- 2012-06-13 MX MX2013015333A patent/MX2013015333A/es unknown
- 2012-06-13 EP EP12803745.4A patent/EP2726100A4/fr not_active Withdrawn
- 2012-06-13 US US14/130,058 patent/US20140248280A1/en not_active Abandoned
- 2012-06-13 EA EA201490180A patent/EA201490180A1/ru unknown
- 2012-06-13 JP JP2014518607A patent/JP2014527035A/ja active Pending
- 2012-06-13 BR BR112013033544A patent/BR112013033544A2/pt not_active IP Right Cessation
- 2012-06-13 AU AU2012275850A patent/AU2012275850A1/en not_active Abandoned
- 2012-06-29 TW TW101123370A patent/TW201317002A/zh unknown
- 2012-06-29 UY UY0001034178A patent/UY34178A/es not_active Application Discontinuation
-
2014
- 2014-01-22 MA MA36703A patent/MA35281B1/fr unknown
- 2014-01-29 CO CO14018361A patent/CO6862110A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR112013033544A2 (pt) | 2017-12-19 |
EP2726100A4 (fr) | 2015-04-29 |
US20140248280A1 (en) | 2014-09-04 |
WO2013003037A3 (fr) | 2014-05-01 |
KR20140063578A (ko) | 2014-05-27 |
CO6862110A2 (es) | 2014-02-10 |
JP2014527035A (ja) | 2014-10-09 |
MX2013015333A (es) | 2014-07-09 |
TW201317002A (zh) | 2013-05-01 |
AU2012275850A1 (en) | 2013-03-21 |
CN103945866A (zh) | 2014-07-23 |
WO2013003037A2 (fr) | 2013-01-03 |
CA2839869A1 (fr) | 2013-01-03 |
EA201490180A1 (ru) | 2014-08-29 |
UY34178A (es) | 2013-01-31 |
EP2726100A2 (fr) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35281B1 (fr) | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA41013A (fr) | Compositions comprenant des souches bactériennes | |
MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA37840A3 (fr) | Immunoconjugués comprenant des anticorps anti-cd79b | |
MA34277B1 (fr) | Pyrrolobenzodiazépines et conjugués de celles-ci | |
MA37538B1 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
MA35712B1 (fr) | Anticorps anti-htra1 et leurs procédés d'utilisation | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
EA201590822A1 (ru) | Адъювантная терапия ингибитором киназы семейства tec | |
MA35210B1 (fr) | Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer | |
BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
MA38986B1 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
MA44700A (fr) | Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer | |
MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
UY34154A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
FR2980972B1 (fr) | Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes. |